ReviewThe Lancet. Oncology2024
A brave new framework for glioma drug development.
Abstract readReview
In one paragraph
Review in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Discrepancies in inter-rater agreement on resectability of recurrent glioblastoma: Complementary post-hoc analysis of the prospective, randomized DIRECTOR trial.Neuro-oncology · 2026Trial
- Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice.Journal of neuro-oncology · 2026Article
- Flash Assembloids: A Rapid Biofabrication of a Platform for Modeling Early Glioblastoma Invasion at the Glioblastoma-Brain Organoid Interfaces.Advanced healthcare materials · 2026Article
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Contemporary surgical strategies for resection of intracranial gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.Neuro-oncology · 2026Review
- Applications of transcranial focused ultrasound for primary brain tumors.Neuro-oncology advances · 2026Review
- Mitochondrial complex I subunit NDUFS4 overexpression drives glioma progression by regulating mitochondrial function and COX5B.NPJ precision oncology · 2026Article
- METTL14/IGF2BP-mediated m6A methylation of circSLIT2 promotes malignant phenotypes of glioblastoma via the miR-127-5p/SH3GLB1 axis.American journal of cancer research · 2026Article
- Introduction of whole genome sequencing as NHS standard of care for glioma patients in two neurosurgical oncology centres: West Midlands.BJC reports · 2025Article
- Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM.Cancer discovery · 2025Article
- Point/counterpoint: The role of re-resection in recurrent glioblastoma.Neuro-oncology · 2025Article
- Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.Nature medicine · 2025Article
- Precision synergy: IDH and PARP inhibitors as a dual-target strategy in IDH-mutant glioma treatment.Annals of medicine and surgery (2012) · 2025Article
- Targeting the glioblastoma resection margin with locoregional nanotechnologies.Nature reviews. Clinical oncology · 2025Review
- Immunotherapy for High-Grade Gliomas.Cancers · 2025Review
- Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.Nature medicine · 2025Article
- Advancing Glioma Management: The Pivotal Role of Surgical Neuro-Oncology in Driving Innovation and Translational Research.Current oncology reports · 2025Review
- High intra-tumoral and serum matrix metalloproteinase 9 levels are associated with reduced survival of patients with glioblastoma and brain metastases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Kelly M HotchkissThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Philipp KarschniaDepartment of Neurosurgery, Friedrich-Alexander University, Erlangen, Germany; Ludwig-Maximilians-University, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
Karisa C SchreckDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marjolein GeurtsDepartment of Neurology, Erasmus MC Cancer Center, Rotterdam, Netherlands; Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, Netherlands.
Timothy F CloughesyDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jason HuseDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth S DukeDivision of Oncology 2, Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Justin LathiaLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
David M AshleyThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Edjah K NduomDepartment of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.
Georgina LongMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Mater and Royal North Shore Hospitals, Sydney, NSW, Australia.
Kirit SinghThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Anthony ChalmersSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Manmeet S AhluwaliaBaptist Health South Florida, Miami, FL, USA.
Amy HeimbergerDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Stephen BagleyUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Tomoki TodoDepartment of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Roel VerhaakDepartment of Surgical Neuro-Oncology, Yale University, New Haven, CT, USA.
Patrick D KellyDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Shawn Hervey-JumperDepartment of Neurological Surgery, UCSF Brain Tumor Center, University of California San Francisco, San Francisco, CA, USA; Weill Institute for Neuroscience, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
John de GrootDepartment of Neurological Surgery, UCSF Brain Tumor Center, University of California San Francisco, San Francisco, CA, USA; Weill Institute for Neuroscience, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Anoop PatelThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Peter FecciThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Ian ParneyDepartment of Neurological Surgery, Mayo Clinic, Rochester, MN, USA.
Victoria WykesInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Neurosurgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Colin WattsInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Neurosurgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Terry C BurnsDepartment of Neurological Surgery, Mayo Clinic, Rochester, MN, USA.
Nader SanaiBarrow Neurological Institute, Phoenix, AZ, USA.
Matthias PreusserDepartment of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
Joerg Christian TonnLudwig-Maximilians-University, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
Katharine J DrummondDepartment of Neurosurgery, Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Surgery, University of Melbourne, Parkville, VIC, Australia.
Michael PlattenDepartment of Neurology, Mannheim Center for Translational Neuroscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany; Clinical Cooperation Unit Brain Tumor Immunology (D170), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sunit DasDivision of Neurosurgery, University of Toronto, Toronto, ON, Canada.
Kirk TannerNational Brain Tumor Society, Newton, MA, USA.
Michael A VogelbaumH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Michael WellerDepartment of Neurological Surgery, Mayo Clinic, Rochester, MN, USA; Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
James R WhittleDepartment of Medical Biology, University of Melbourne, Parkville, VIC, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Personalised Oncology Division, Walter and Eliza Hall Institute, Parkville, VIC, Australia.
Mitchel S BergerDepartment of Neurological Surgery, UCSF Brain Tumor Center, University of California San Francisco, San Francisco, CA, USA; Weill Institute for Neuroscience, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Mustafa KhasrawThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA. Electronic address: mustafa.khasraw@duke.edu.
Funding
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MViral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9MNCI NIH HHS P50 CA211015NCI NIH HHS T32 CA009111
Abstract
Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.
Indexed as
Brain NeoplasmsDrug DevelopmentGliomaAntineoplastic AgentsHumansAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.